CN112754014A - 一种防治心脑血管***疾病的组合物及其制备方法 - Google Patents
一种防治心脑血管***疾病的组合物及其制备方法 Download PDFInfo
- Publication number
- CN112754014A CN112754014A CN202011604484.2A CN202011604484A CN112754014A CN 112754014 A CN112754014 A CN 112754014A CN 202011604484 A CN202011604484 A CN 202011604484A CN 112754014 A CN112754014 A CN 112754014A
- Authority
- CN
- China
- Prior art keywords
- extract
- preparation
- water
- extracting solution
- green tea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 27
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 17
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 16
- 241001205401 Aspergillus cristatus Species 0.000 claims abstract description 64
- 244000269722 Thea sinensis Species 0.000 claims abstract description 35
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 34
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 34
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 31
- 240000008042 Zea mays Species 0.000 claims abstract description 31
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 31
- 239000000284 extract Substances 0.000 claims abstract description 31
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 30
- 235000009569 green tea Nutrition 0.000 claims abstract description 29
- 235000018597 common camellia Nutrition 0.000 claims abstract description 28
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 23
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 23
- 235000005822 corn Nutrition 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 238000001035 drying Methods 0.000 claims abstract description 15
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 12
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 12
- 108090000790 Enzymes Proteins 0.000 claims abstract description 8
- 102000004190 Enzymes Human genes 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 239000009636 Huang Qi Substances 0.000 claims abstract description 6
- 229940107666 astragalus root Drugs 0.000 claims abstract description 6
- 240000001548 Camellia japonica Species 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 16
- 229920001218 Pullulan Polymers 0.000 claims description 14
- 239000004373 Pullulan Substances 0.000 claims description 14
- 235000019423 pullulan Nutrition 0.000 claims description 14
- 235000006533 astragalus Nutrition 0.000 claims description 13
- 238000009835 boiling Methods 0.000 claims description 10
- 241001061264 Astragalus Species 0.000 claims description 8
- 235000007244 Zea mays Nutrition 0.000 claims description 8
- 229940089639 cornsilk Drugs 0.000 claims description 8
- 210000004233 talus Anatomy 0.000 claims description 8
- 239000001231 zea mays silk Substances 0.000 claims description 8
- 241000045403 Astragalus propinquus Species 0.000 claims description 5
- 235000019206 astragalus extract Nutrition 0.000 claims description 5
- 241000219780 Pueraria Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 239000002994 raw material Substances 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 230000006870 function Effects 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 241000209507 Camellia Species 0.000 abstract 3
- 238000012360 testing method Methods 0.000 description 21
- 238000000855 fermentation Methods 0.000 description 20
- 230000004151 fermentation Effects 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 241000700159 Rattus Species 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 239000002775 capsule Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 238000009630 liquid culture Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000009849 deactivation Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000002960 lipid emulsion Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 206010007688 Carotid artery thrombosis Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000519406 Paphiopedilum Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000009777 vacuum freeze-drying Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 235000020343 anhua dark tea Nutrition 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3562—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种防治心脑血管***疾病的组合物的制备方法,包括以下步骤:将金花茶鲜叶和绿茶鲜叶杀青、烘干得到处理后的金花茶和绿茶;制备玉米须提取液、葛根提取液、黄芪提取液和铁皮石斛提取液;将所述处理后的金花茶和绿茶、所述玉米须提取液、葛根提取液、黄芪提取液和铁皮石斛提取液、辅酶Q10、冠突散囊菌和辅料混合、干燥制粒得到防治心脑血管***疾病的组合物。本发明的制备方法工艺创新、效率高、成本较低、通过综合的降血糖降血脂、抗氧化、调机能,增强免疫力,使防治心脑血管***疾病功效显著突出、能防能治、尤其冠突散囊菌菌丝与辅酶Q10协同增效的运用是一种新的突破,以致于产品保健作用更显著,且原料全部为食品级原料,安全性极高。
Description
技术领域
本发明属于属保健食品技术领域,特别涉及一种一种防治心脑血管***疾病的组合物及其制备方法。
背景技术
随着人们生活水平的提高,高血压、高血脂和高血糖引起的心脑血管***疾病已经成为威胁人类健康的“头号杀手”。日本科研人员将“金花”加工成防治“三高”保健品,售价超过黄金,使得冠突散囊菌的保健作用受到了越来越多的关注和重视。然而,我国对冠突散囊菌的研究多基于其对茶叶的影响,作为在医学领域具有应用潜力的益生菌,其医药价值却没有引起人们足够的重视,没有得到充分的利用和开发。
辅酶Q10是一种脂溶性抗氧化剂,辅酶Q10是人类生命不可缺少的重要元素之一,能激活人体细胞和细胞能量的营养,具有提高人体免疫力、增强抗氧化、延缓衰老和增强人体活力等功能,医学上广泛用于心血管***疾病。
中药在防治心脑血管疾病方面占有优势,可以有效的改善病情,防治疾病发展,毒副作用小,但相对治疗疗程较长,鉴于此,本发明在中药的基础上辅以冠突散囊菌、辅酶Q10,治疗可以有效缩短病程,减轻病人痛苦,预防人群使用本组合物可以显著提高身体机能,减少此类疾病的发生。
发明内容
针对存在的上述问题,本发明提供一种防治心脑血管***疾病的组合物及其制备方法。
具体来说,本发明涉及如下方面:
1、一种防治心脑血管***疾病的组合物的制备方法,其特征在于,所述制备方法包括以下步骤:
将金花茶鲜叶和绿茶鲜叶杀青、烘干得到处理后的金花茶和绿茶;
制备玉米须提取液、葛根提取液、黄芪提取液和铁皮石斛提取液;
将所述处理后的金花茶和绿茶、所述玉米须提取液、葛根提取液、黄芪提取液和铁皮石斛提取液、辅酶Q10、冠突散囊菌和普鲁兰糖混合得到防治心脑血管***疾病的组合物。
2、根据权利要求1所述的制备方法,其特征在于,按重量份计,所述金花茶鲜叶为16~24份,所述绿茶鲜叶为0.4~1.2份,所述玉米须为4~12份,所述葛根为1~5份,所述黄芪为2~3份,所述铁皮石斛为0.6~1份,所述冠突散囊菌丝为0.4~0.6份,所述辅酶Q10为0.2~0.9份,所述普鲁兰糖为0.002~0.008份。
3、根据项1-3任一项所述的制备方法,其特征在于,所述杀青包括杀青机杀青和微波炉杀青。
4、根据项3所述的制备方法,其特征在于,所述微波炉杀青的功率为中火460W-620W,杀青时间为60S-200S。
5、根据项3所述的制备方法,其特征在于,所述杀青机杀青的杀青温度110~120℃,杀青时间为1~2min。
6、根据项1-5任一项所述的制备方法,其特征在于,所述烘干包括在100~110℃下将杀青后的金花茶和绿茶烘干至含水量5%~8%。
7、根据项1-6任一项所述的制备方法,其特征在于,所述玉米须提取液和所述葛根提取液的制备包括以下步骤:将所述玉米须、所述葛根和水一起煮沸,过滤得到所述玉米须提取液和所述葛根提取液。
8、根据项1-7任一项所述的制备方法,其特征在于,所述黄芪提取液和所述铁皮石斛提取液的制备包括以下步骤:将所述黄芪、所述铁皮石斛和水一起煮沸,过滤,将滤渣使用乙醇处理得到所述黄芪提取液和所述铁皮石斛提取液。
9、根据项1-8任一项所述的制备方法,其特征在于,所述冠突散囊菌的分类命名为Eurotium cristatum,其保藏编号为CGMCC NO.15398。
10、项1-9任一项所述的制备方法制备得到的防治心脑血管***疾病的组合物。
与现有技术相比,本发明具有以下有益效果:
(1)以金花茶鲜叶、绿茶鲜叶采用微波杀青,更大程度的保留了丰富的茶多酚等有效保健活性物质成份;
(2)金花茶、绿茶、铁皮石斛的微寒性质,使本组方气味甘凉而性质温和,更有利于成年人和老年人的保健、消脂、降血糖;
(4)将玉米须、葛根加水煮提的处理方式,既能充分提取其有效成份,又能去除原料渣,浓缩了各组分有效成份;
(5)铁皮石斛嫩芽、黄芪加水提取和乙醇提取,能将其水溶和醇溶性有效功能物质充分提取,提高原料利用率;
(6)冠突散囊菌经发酵罐液体发酵,发酵时间短,活性强,较传统工艺大幅度的提高了冠突散囊菌的产量,降低了成本。
(7)各有效组分在普鲁兰糖的协调下,与干茶叶让其粘附并充分吸收,再压成片粒、低温减压干燥、包装成成品。在此,普鲁兰糖起到适当的粘合作用,还为成品的保鲜保质及益生菌的保护提供帮助。
综上所述,本发明工艺创新、效率提高、成本较低、通过综合的降血糖降血脂、抗氧化、调机能,增强免疫力,使防治心脑血管***疾病功效显著突出、能防能治、尤其冠突散囊菌菌丝与辅酶Q10协同增效的运用在本组方原料的应用上是一种新的突破,以致于产品保健作用更显著,且原料全部为食品级原料,安全性极高,可为大众人群日常预防心脑血管***疾病的保健性服用,也可作患有心脑血管***疾病的病人使用。
具体实施方式
下面结合实施例进一步说明本发明,应当理解,实施例仅用于进一步说明和阐释本发明,并非用于限制本发明。
除非另外定义,本说明书中有关技术的和科学的术语与本领域内的技术人员所通常理解的意思相同。虽然在实验或实际应用中可以应用与此间所述相似或相同的方法和材料,本文还是在下文中对材料和方法做了描述。在相冲突的情况下,以本说明书包括其中定义为准,另外,材料、方法和例子仅供说明,而不具限制性。以下结合具体实施例对本发明作进一步的说明,但不用来限制本发明的范围。
本发明提供一种防治心脑血管***疾病的组合物的制备方法,所述制备方法包括以下步骤:
将金花茶鲜叶和绿茶鲜叶杀青、烘干得到处理后的金花茶和绿茶;
制备玉米须提取液、葛根提取液、黄芪提取液和铁皮石斛提取液;
将所述处理后的金花茶和绿茶、所述玉米须提取液、葛根提取液、黄芪提取液和铁皮石斛提取液、辅酶Q10、冠突散囊菌和普鲁兰糖混合得到防治心脑血管***疾病的组合物。
其中,上述方法中各原料的作用如下:
玉米须:含有的多糖类物质,可以促进肝糖原的合成,它有很明显的辅助治疗糖尿病作玉米须具有很明显的降血压作用,因此血压过低的人,应当谨慎使用玉米须。玉米须还有利尿消肿、加速血液凝固等作用,在临床上可以用于治疗多种常见疾病。
葛根:含有的葛根素,可以提高胰岛素的敏感性,清除体内的自由基,对于改善人体的糖代谢有很明显的作用。葛根还有扩张外周血管的作用,因此可以帮助糖友防治微血管病变所导致的周围神经病变、视网膜病变与肾功能病变。
绿茶:其中维生素C、茶多酚、儿茶素含量及保健功效较高。
黄芪:黄芪多糖可以通过增加糖原合成酶、胰岛素受体活性等来增强胰岛素的敏感性,因此具有降低血糖的作用。药理研究表明:黄芪有诱生干扰素和提升免疫力的作用,常吃可以增强机体的抗病能力,预防多种常见疾病。
铁皮石斛:自古以来,铁皮石斛就是治疗糖尿病的专用药,铁皮石斛味甘,性微寒,有生津养胃,滋阴清热,润肺益肾,明目强腰作用。
冠突散囊菌菌丝:属益生菌,是安化黑茶通过“发花”工艺长成的自然菌体,具有较强的降血脂、降血压、调节糖类代谢等功效,本发明利用发酵罐液体高密度发酵,很大幅度的提高了其产量。
辅酶Q10:辅酶Q10有助于为心肌提供充足氧气,预防突发性心脏病,尤其在心肌缺氧过程中辅酶Q10发挥关键作用。心脏病、牙周炎、肠胃溃疡、老年痴呆症、糖尿病患者补充辅酶Q10有助于改善病情。
普鲁兰糖:由淀粉水解物,蔗糖或其他糖类直接发酵生产制得的一种无毒副作用的工业用多糖,其水溶液有滑润、清爽的感觉,具有改善口感的作用,普鲁兰糖有使双歧杆菌增殖和治疗便秘的作用,还有保鲜保质的作用。
本发明所采用的冠突散囊菌的分类命名为Eurotium cristatum,其于2018年4月2日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC NO.15398,保藏地址为北京市朝阳区北辰西路1号院3号。
实施例1
一种防治心脑血管***疾病的组合物的制备方法,其中该方法中使用的原料包括:
金花茶鲜叶 16份
玉米须 4份
葛根 1份
绿茶鲜叶 0.8份
铁皮石斛嫩芽 0.8份
黄芪 2份
冠突散囊菌丝 0.5份
辅酶Q10 0.4份
普鲁兰糖 0.002份
具体的,所述制备方法包括以下步骤:
(1)将金花茶鲜叶16kg、绿茶鲜叶0.8kg用杀青机杀青,杀青温度为110℃,杀青时间为2min,杀青后在100℃下烘干至含水量为5~8%,得到处理后的金花茶和绿茶;
(2)将玉米须4kg,葛根1kg一起放入煎煮锅中,加入20kg份水,煮沸30min,200目过滤得玉米须提取液和葛根提取液,其中,两种提取液混合在一起;
(3)将黄芪2kg、铁皮石斛嫩芽0.8kg切碎,放入煎煮锅中,加入15kg水,煮沸60min,200目过滤得煮提液,将滤渣加入2倍重量份的90%(V/V)乙醇,搅拌均匀,浸泡30小时,滤去渣,取滤出液蒸馏回收乙醇后得黄芪提取液和铁皮石斛提取液;
(4)冠突散囊菌菌丝的获取:
a.冠突散囊菌菌种活化:利用固体PDA培养基在超净工作台中无菌接种,然后将试管放置在30℃培养箱中静置培养104h,获得活化后的冠突散囊菌菌种。
b.冠突散囊菌摇瓶培养:将步骤a中的活化后的冠突散囊菌菌落接种于装有200ml液体培养基的500ml摇瓶中,置于30℃的摇床中培养96h,获得冠突散囊菌种子液。
c.冠突散囊菌的发酵罐高密度发酵;将步骤b中获得的冠突散囊菌种子液按20%(V/V)的接种量接种于液体培养基中高密度发酵培养,培养温度为30℃、pH5.0、溶氧控制在50-80%、培养至菌丝量不再增加时停止发酵。
d.冠突散囊菌菌丝的收集:将获得的冠突散囊菌菌液体通过8层纱布进行过滤处理,收集发酵产物中的菌丝,将菌丝利用蒸馏水清洗3-5次后尽可能多的除掉水分,然后,将菌丝置于真空冷冻干燥机进行冻干,即得。
(5)辅酶Q10:购买自美国GNC/健安喜,100mg*120粒,生产批号:3146FR7853;
(6)将0.002kg普鲁兰糖加入到步骤(2)(3)(4)所获取的各种组分中,搅拌均匀,得混合物;
(7)将步骤(1)所得的处理后的金花茶和绿茶与步骤(6)所得的混合物混合均匀,得组合物;
(8)将步骤(7)所得的组合物用制药压片机压制成片粒状,0.2g/片规格,然后经30~35℃减压干燥、包装,制得一种防治心脑血管***疾病的保健品。
实施例2
一种防治心脑血管***疾病的组合物的制备方法,其中该方法中使用的原料包括:
金花茶鲜叶 18份
玉米须 5份
葛根 2份
绿茶鲜叶 1份
铁皮石斛嫩芽 0.8份
黄芪 2.5份
冠突散囊菌丝 0.5份
辅酶Q10 0.5份
普鲁兰糖 0.003份
具体的,所述制备方法包括以下步骤:
(1)将金花茶鲜叶18kg、绿茶鲜叶1kg用杀青机杀青,杀青温度120℃,杀青时间1min,杀青后用110℃烘干至含水量为5~8%,得到处理后的金花茶和绿茶;
(2)将玉米须5kg,葛根2kg一起放入煎煮锅中,加入24kg份水,煮沸30min,200目过滤得玉米须提取液和葛根提取液,其中,两种提取液混合在一起;
(3)将黄芪2.5kg、铁皮石斛嫩芽0.8kg切碎,放入煎煮锅中,加入18kg水,煮沸60min,200目过滤得煮提液,将滤渣加入2倍重量份的90%(V/V)乙醇,搅拌均匀,浸泡30小时,滤去渣,取滤出液蒸馏回收乙醇后得黄芪提取液和铁皮石斛提取液;
(4)冠突散囊菌菌丝获取:
a.冠突散囊菌菌种活化:利用固体PDA培养基在超净工作台中无菌接种,然后将试管放置在30℃培养箱中静置培养104h,获得活化后的冠突散囊菌菌种。
b.冠突散囊菌摇瓶培养:将步骤a中的活化后的冠突散囊菌菌落接种于装有200ml液体培养基的500ml摇瓶中,置于30℃的摇床中培养96h,获得冠突散囊菌种子液。
c.冠突散囊菌的发酵罐高密度发酵;将步骤b中获得的冠突散囊菌种子液按20%(V/V)的接种量接种于液体培养基中高密度发酵培养,培养温度为30℃、pH5.0、溶氧控制在50-80%、培养至菌丝量不再增加时停止发酵。
d.冠突散囊菌菌丝的收集:将获得的冠突散囊菌菌液体通过8层纱布进行过滤处理,收集发酵产物中的菌丝,将菌丝利用蒸馏水清洗3-5次后尽可能多的除掉水分,然后,将菌丝置于真空冷冻干燥机进行冻干,即得。
(5)辅酶Q10:购买自美国GNC/健安喜,100mg*120粒,生产批号:3146FR7853;
(6)将0.003kg普鲁兰糖加入到步骤(2)(3)(4)(5)所获取的各种组分中,搅拌均匀,得混合物;
(7)将步骤(1)所得的处理后的金花茶和绿茶与步骤(6)所得的混合物混合均匀,得组合物;
(8)将步骤(7)所得的组合物用制药压片机压制成片粒状,0.2g/片规格,然后经30~35℃减压干燥、包装,制得一种防治心脑血管***疾病的保健品。
实施例3
一种防治心脑血管***疾病的组合物的制备方法,其中该方法中使用的原料包括:
金花茶鲜叶 20份
玉米须 6份
葛根 2份
绿茶鲜叶 1份
铁皮石斛嫩芽 1.0份
黄芪 2.0份
冠突散囊菌丝 0.5份
辅酶Q10 0.6份
普鲁兰糖 0.005份
具体的,所述制备方法包括以下步骤:
(1)将金花茶鲜叶20kg、绿茶鲜叶1.0kg,用微波炉杀青,中火功率530W,杀青时间100S,杀青后用100~110℃烘干至含水量为5~8%,得干茶叶;
(2)将玉米须6kg,葛根2kg一起放入煎煮锅中,加入32kg份水,煮沸30min,200目过滤得玉米须提取液和葛根提取液,其中,两种提取液混合在一起;
(3)将黄芪2.0kg、铁皮石斛嫩芽1.0kg切碎,放入煎煮锅中,加入18kg水,煮沸60min,200目过滤得煮提液,将滤渣加入2倍重量份的90%(V/V)乙醇,搅拌均匀,浸泡30小时,滤去渣,取滤出液蒸馏回收乙醇后得黄芪提取液和铁皮石斛提取液;
a.冠突散囊菌菌种活化:利用固体PDA培养基在超净工作台中无菌接种,然后将试管放置在30℃培养箱中静置培养104h,获得活化后的冠突散囊菌菌种。
b.冠突散囊菌摇瓶培养:将步骤a中的活化后的冠突散囊菌菌落接种于装有200ml液体培养基的500ml摇瓶中,置于30℃的摇床中培养96h,获得冠突散囊菌种子液。
c.冠突散囊菌的发酵罐高密度发酵;将步骤b中获得的冠突散囊菌种子液按20%(V/V)的接种量接种于液体培养基中高密度发酵培养,培养温度为30℃、pH5.0、溶氧控制在50-80%、培养至菌丝量不再增加时停止发酵。
d.冠突散囊菌菌丝的收集:将获得的冠突散囊菌菌液体通过8层纱布进行过滤处理,收集发酵产物中的菌丝,将菌丝利用蒸馏水清洗3-5次后尽可能多的除掉水分,然后,将菌丝置于真空冷冻干燥机进行冻干,即得。
(5)辅酶Q10:购买自美国GNC/健安喜,100mg*120粒,生产批号:3146FR7853;
(6)将0.005kg普鲁兰糖加入到步骤(2)(3)(4)(5)所获取的各种组分中,搅拌均匀,得混合物;
(7)将步骤(1)所得的干茶叶与步骤(6)所得的混合物混合均匀,得组合物;
(8)将步骤(7)所得的组合物用制药压片机压制成片粒状,0.2g/片规格,然后经30~35℃减压干燥、包装,制得一种防治心脑血管***疾病的保健品。
试验例1:治疗小鼠实验性体内血栓形成药效学实验:
受试动物:SPF级雄性小鼠,70只,体重23—28g,随机分为7组,每组10只。试验小鼠由湖南斯莱克景达实验动物有限公司;饲养条件:SPF级动物实验室,室温23~25℃,相对湿度40%~70%,12h光照/黑暗交替,自由摄食和饮水。
待试样品:实施例1,实施例2,实施例3中所制得的组合物片剂,0.2g/片,自制;
冠突散囊菌菌丝片剂,0.2g/片,自制,每片片剂中的冠突散囊菌菌丝含量与实施例1、2和3相同,还含有羧甲基纤维素钠、微晶纤维素、羧甲淀粉钠硬脂酸镁;
辅酶Q10胶囊,购买自美国GNC/健安喜,100mg*120粒,生产批号:3146FR7853;
中药汤剂,自制,制备方法同实施例3,区别在于未加入冠突散囊菌丝、辅酶Q10,只含有其他组分。
给药剂量:各受试组给药药物及剂量见表1;
试验方法:按照表1所列给药剂量,灌胃给药1小时后,尾静脉注射胶原蛋白-肾上腺素混合血栓诱导剂每只0.1mg。注射后20min内记录小鼠偏瘫恢复数据,并计算各给药组队小鼠血栓形成的保护率(死亡保护率=对照组死亡数—给药组死亡数/对照组死亡数),按照公式q=EAB/(EA+EB-EA*EB)求出各组q值。
试验结果及结论:试验结果见表1。结果表明,组合物片剂均对胶原蛋白-肾上腺素诱导小鼠脑血栓死亡有保护作用(实施例3所制成的组合物片剂效果最优),并且均高于相应的冠突散囊菌菌丝片剂、辅酶Q10胶囊及中药汤剂单独用药效果。概率相加法表明食用冠突散囊菌菌丝、辅酶Q10胶囊及中药各组分按照实施例3所示配伍,药效增强,呈协同增效作用。
表1:待试样品治疗小鼠实验性体内血栓形成药效学实验数据(n=10)
试验例2:待试样品对大鼠实验性颈总动脉血栓形成时间的影响
受试动物:SPF及SD雄性大鼠,140只,体重200—220g,随机分为7组,每组20只。试验动物由湖南斯莱克景达实验动物有限公司;饲养条件:SPF级动物实验室,室温23~25℃,相对湿度40%~70%,12h光照/黑暗交替,自由摄食和饮水。
待试样品:实施例1,实施例2,实施例3中所制得的组合物片剂,0.2g/片;
冠突散囊菌菌丝片剂,0.2g/片,自制,每片片剂中的冠突散囊菌菌丝含量与实施例1、2和3相同,还含有羧甲基纤维素钠、微晶纤维素、羧甲淀粉钠硬脂酸镁;
辅酶Q10胶囊,购买自美国GNC/健安喜,100mg*120粒,生产批号:3146FR7853;
中药汤剂,自制,制备方法同实施例3,区别在于未加入冠突散囊菌丝、辅酶Q10,只含有其他组分。
给药剂量:30mg/kg(30ul/kg)。
试验方法:大鼠用2.5%戊巴比妥钠(25mg/kg)腹腔注射麻醉,仰卧位固定,分离右侧颈总动脉,采用电流损伤颈动脉内膜法,用BT87-3实验性体内血栓形成仪测定不同组别动物颈动脉血栓形成时间。将刺激点击和温度探头关于颈总动脉上,按表2所示给药,给药后10min开始刺激,刺激强度为2mA,刺激5min后关闭刺激开关,取下电极,3min后调节温控表至零,观察颈动脉温度突降时间,记录电刺激开始至主动脉温度突降时间,该时间定为颈动脉血栓形成时间(超过3000秒者以3000秒计)。
试验结果及结论:试验结果见表2。结果表明:实施例1、实施例2、实施例3中所制得的组合物片剂给药组、冠突散囊菌菌丝片剂给药组、辅酶Q10胶囊给药组及中药汤剂给药组与对照组相比较,动脉血栓形成时间均推迟。表明,实施例1、实施例2、实施例3中所制得的组合物片剂给药组、冠突散囊菌菌丝片剂给药组、辅酶Q10胶囊给药组及中药汤剂给药组均对大鼠实验性动脉血栓形成有保护作用。并且实施例3所制成的组合物片剂组的作用均强于冠突散囊菌菌丝片剂给药组、辅酶Q10胶囊给药组及中药汤剂给药组,提示有协同增效作用。
表2:待试样品对大鼠实验性颈总动脉血栓形成时间的影响(n=10):
试验例3:待试样品对大鼠实验性高血脂症的影响
受试动物:SPF级SD大鼠,140只,雌雄各半,体重200~230g,由湖南斯莱克景达实验动物有限公司;饲养条件:SPF级动物实验室,室温23~25℃,相对湿度40%~70%,12h光照/黑暗交替,自由摄食和饮水。
待试样品:实施例1,实施例2,实施例3中所制得的组合物片剂,0.2g/片;
冠突散囊菌菌丝片剂,0.2g/片,自制,每片片剂中的冠突散囊菌菌丝含量与实施例1、2和3相同,还含有羧甲基纤维素钠、微晶纤维素、羧甲淀粉钠硬脂酸镁;
辅酶Q10胶囊:购买自美国GNC/健安喜,100mg*120粒,生产批号:3146FR7853;
中药汤剂,自制,制备方法同实施例3,区别在于未加入冠突散囊菌丝、辅酶Q10,只含有其他组分。
给药剂量:30mg/kg(30ul/kg)。
试剂、仪器:总胆固醇、甘油三脂测试盒购自南京建成生物工程研究所;7150型全自动生化分析仪(日本日立公司)。
试验方法:将140只SD大鼠随机分出20只作空白对照,其余120只用于模型的复制。参照文献《脂肪乳剂建立高脂血症模型小鼠的比较研究》(周桢昊赵璐杨旋曾南)制备高脂乳剂(其中,高脂乳剂含有胆固醇10%、猪油20%、胆酸钠2%、丙硫氧嘧啶1%、山梨醇甲酯20%、丙二醇20%),按照10ml/kg灌胃给予高脂乳剂,空白对照组灌胃给予生理盐水,每天1次,连续3周。断尾取血,测定其血清TC值,以TC值显著高于空白对照组为模型复制成功,即为高血脂模型大鼠。
分组及给药:除外空白对照(等容生理盐水)组,将120只高血脂模型大鼠按体重、性别随机分为6组,即模型组(等容生理盐水)、其余6组按30mg/kg(30ul/kg)灌胃给药,每天1次,持续28天。
指标的测定:末次给药后眼眶取血,分离血清,用试剂盒检测血清中甘油三酯及甘油三酯水平。
试验结果及结论:试验结果见表3和表4。结果表明:实施例1、实施例2、实施例3中所制得的组合物片剂给药组、冠突散囊菌菌丝片剂给药组、辅酶Q10胶囊给药组及中药汤剂给药组均可有效的降低饮食性高血脂大鼠的血脂胆固醇和甘油三酯,且按照实施例3配伍制成的组合物片剂效果最优,表明食用冠突散囊菌菌丝、辅酶Q10胶囊及中药各组分按照实施例3所示配伍,药效增强,呈协同增效作用。
表3:待试样品对饮食性高血脂大鼠血清胆固醇的的影响(n=10)
表4:待试样品对饮食性高血脂大鼠血清甘油三酯的的影响(n=10)
Claims (10)
1.一种防治心脑血管***疾病的组合物的制备方法,其特征在于,所述制备方法包括以下步骤:
将金花茶鲜叶和绿茶鲜叶杀青、烘干得到处理后的金花茶和绿茶;
制备玉米须提取液、葛根提取液、黄芪提取液和铁皮石斛提取液;
将所述处理后的金花茶和绿茶、所述玉米须提取液、葛根提取液、黄芪提取液和铁皮石斛提取液、辅酶Q10、冠突散囊菌和普鲁兰糖混合得到防治心脑血管***疾病的组合物。
2.根据权利要求1所述的制备方法,其特征在于,按重量份计,所述金花茶鲜叶为16~24份,所述绿茶鲜叶为0.4~1.2份,所述玉米须为4~12份,所述葛根为1~5份,所述黄芪为2~3份,所述铁皮石斛为0.6~1份,所述冠突散囊菌丝为0.4~0.6份,所述辅酶Q10为0.2~0.9份,所述普鲁兰糖为0.002~0.008份。
3.根据权利要求1-3任一项所述的制备方法,其特征在于,所述杀青包括杀青机杀青和微波炉杀青。
4.根据权利要求3所述的制备方法,其特征在于,所述微波炉杀青的功率为中火460W-620W,杀青时间为60S-200S。
5.根据权利要求3所述的制备方法,其特征在于,所述杀青机杀青的杀青温度110~120℃,杀青时间为1~2min。
6.根据权利要求1-5任一项所述的制备方法,其特征在于,所述烘干包括在100~110℃下将杀青后的金花茶和绿茶烘干至含水量5%~8%。
7.根据权利要求1-6任一项所述的制备方法,其特征在于,所述玉米须提取液和所述葛根提取液的制备包括以下步骤:将所述玉米须、所述葛根和水一起煮沸,过滤得到所述玉米须提取液和所述葛根提取液。
8.根据权利要求1-7任一项所述的制备方法,其特征在于,所述黄芪提取液和所述铁皮石斛提取液的制备包括以下步骤:将所述黄芪、所述铁皮石斛和水一起煮沸,过滤,将滤渣使用乙醇处理得到所述黄芪提取液和所述铁皮石斛提取液。
9.根据权利要求1-8任一项所述的制备方法,其特征在于,所述冠突散囊菌的分类命名为Eurotium cristatum,其保藏编号为CGMCC NO.15398。
10.权利要求1-9任一项所述的制备方法制备得到的防治心脑血管***疾病的组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011604484.2A CN112754014A (zh) | 2020-12-29 | 2020-12-29 | 一种防治心脑血管***疾病的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011604484.2A CN112754014A (zh) | 2020-12-29 | 2020-12-29 | 一种防治心脑血管***疾病的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112754014A true CN112754014A (zh) | 2021-05-07 |
Family
ID=75697376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011604484.2A Pending CN112754014A (zh) | 2020-12-29 | 2020-12-29 | 一种防治心脑血管***疾病的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112754014A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117801967A (zh) * | 2024-03-01 | 2024-04-02 | 烟台市供销社茶业有限公司 | 一种培养冠突散囊菌的方法及应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103734696A (zh) * | 2013-11-21 | 2014-04-23 | 荣成百合生物技术有限公司 | 一种提高免疫力、保护脏器的软胶囊及其制备方法 |
CN104857034A (zh) * | 2015-04-14 | 2015-08-26 | 南京贝杉国际贸易有限公司 | 一种防治心脑血管疾病的功能食品及其制备方法 |
CN105055897A (zh) * | 2015-07-13 | 2015-11-18 | 陈树杰 | 一种防治糖尿病的保健茶片及其制备方法 |
CN106138831A (zh) * | 2016-08-18 | 2016-11-23 | 北华大学 | 一种治疗心脑血管疾病的中药组合物及其制备方法 |
CN106581492A (zh) * | 2016-12-30 | 2017-04-26 | 孝感华越机电科技有限公司 | 一种治疗糖尿病的中药 |
CN106729675A (zh) * | 2016-04-24 | 2017-05-31 | 佛山瑞箭体育器材有限公司 | 一种治疗心脑血管疾病的药物组合物及其制备方法 |
US20170354700A1 (en) * | 2014-12-30 | 2017-12-14 | Shineway Pharmaceutical Group Ltd. | Chinese medicinal composition for preventing or treating cardiovascular and cerebrovascular diseases or dementia, and preparation method and use thereof |
CN111803528A (zh) * | 2020-08-20 | 2020-10-23 | 西安巨子生物基因技术股份有限公司 | 一种冠突散囊菌制品及其应用 |
-
2020
- 2020-12-29 CN CN202011604484.2A patent/CN112754014A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103734696A (zh) * | 2013-11-21 | 2014-04-23 | 荣成百合生物技术有限公司 | 一种提高免疫力、保护脏器的软胶囊及其制备方法 |
US20170354700A1 (en) * | 2014-12-30 | 2017-12-14 | Shineway Pharmaceutical Group Ltd. | Chinese medicinal composition for preventing or treating cardiovascular and cerebrovascular diseases or dementia, and preparation method and use thereof |
CN104857034A (zh) * | 2015-04-14 | 2015-08-26 | 南京贝杉国际贸易有限公司 | 一种防治心脑血管疾病的功能食品及其制备方法 |
CN105055897A (zh) * | 2015-07-13 | 2015-11-18 | 陈树杰 | 一种防治糖尿病的保健茶片及其制备方法 |
CN106729675A (zh) * | 2016-04-24 | 2017-05-31 | 佛山瑞箭体育器材有限公司 | 一种治疗心脑血管疾病的药物组合物及其制备方法 |
CN106138831A (zh) * | 2016-08-18 | 2016-11-23 | 北华大学 | 一种治疗心脑血管疾病的中药组合物及其制备方法 |
CN106581492A (zh) * | 2016-12-30 | 2017-04-26 | 孝感华越机电科技有限公司 | 一种治疗糖尿病的中药 |
CN111803528A (zh) * | 2020-08-20 | 2020-10-23 | 西安巨子生物基因技术股份有限公司 | 一种冠突散囊菌制品及其应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117801967A (zh) * | 2024-03-01 | 2024-04-02 | 烟台市供销社茶业有限公司 | 一种培养冠突散囊菌的方法及应用 |
CN117801967B (zh) * | 2024-03-01 | 2024-04-30 | 烟台市供销社茶业有限公司 | 一种培养冠突散囊菌的方法及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102669667B (zh) | 具有保肝和调节血脂双重功能的保健食品及其制备方法 | |
CN103493941B (zh) | 一种减肥保健茶及其制备方法 | |
CN102613330B (zh) | 发酵红曲茶及提取物、提取物组合物及其制备方法 | |
CN101502627B (zh) | 防治酒精性肝病的中药保健品制剂及其制备方法 | |
CN103740566B (zh) | 一种刺梨药酒及其制作方法 | |
KR101332321B1 (ko) | 선옥균과 한약재를 이용한 건강식품 및 그 제조방법 | |
CN108671002B (zh) | 一种含雪莲培养物提取物的组合物及其应用 | |
CN106615431A (zh) | 一种菊芋片茶及其制作方法 | |
CN104957305A (zh) | 一种对叶榕果复配降血糖茶片及其制备方法 | |
CN102613331B (zh) | 蜜环菌发酵茶、蜜环菌发酵茶组合物及其制备及方法 | |
CN103055157B (zh) | 一种复方霍斛蓉芝颗粒及其生产工艺 | |
CN102894364A (zh) | 一种苦瓜绿茶降糖含片的制备方法 | |
CN112754014A (zh) | 一种防治心脑血管***疾病的组合物及其制备方法 | |
CN105055897A (zh) | 一种防治糖尿病的保健茶片及其制备方法 | |
CN107494817A (zh) | 一种降糖降脂茶 | |
CN107019136A (zh) | 一种具有降血糖功效的固体饮料及其制备方法 | |
CN102488744A (zh) | 一种解酒毒的药物及其制备方法 | |
CN105831318A (zh) | 一种多肽降糖茶及其制作方法 | |
CN101569645A (zh) | 一种雪莲果***片及制备方法 | |
CN105713787B (zh) | 一种护肝型藏红花葛根黄酒的制备方法 | |
CN108260682A (zh) | 一种降血糖、降血脂和降血压的保健茶 | |
CN108813500B (zh) | 具有补中益气、养血安神和调节人体机能的养生蜂蜜膏 | |
CN107495340A (zh) | 一种降尿酸利尿组合物及其制备方法 | |
CN103343078A (zh) | 一种金刺参保健黄酒的生产工艺 | |
CN106433949A (zh) | 一种低酸价云南松松籽油及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210507 |